Northern Trust’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.04M Buy
240,968
+11,079
+5% +$149K ﹤0.01% 2735
2025
Q4
$3.63M Buy
229,889
+33,993
+17% +$432K ﹤0.01% 2661
2025
Q3
$2.34M Sell
195,896
-55,318
-22% -$442K ﹤0.01% 2941
2025
Q2
$1.9M Sell
251,214
-69,298
-22% -$417K ﹤0.01% 3017
2025
Q1
$1.77M Sell
320,512
-66,864
-17% -$413K ﹤0.01% 2987
2024
Q4
$2.23M Sell
387,376
-149,329
-28% -$1.43M ﹤0.01% 2964
2024
Q3
$5.56M Sell
536,705
-308,411
-36% -$4.03M ﹤0.01% 2412
2024
Q2
$11M Sell
845,116
-88,240
-9% -$1.19M ﹤0.01% 1941
2024
Q1
$16.3M Sell
933,356
-2,137
-0.2% -$28.3K ﹤0.01% 1726
2023
Q4
$8.8M Sell
935,493
-24,413
-3% -$227K ﹤0.01% 2153
2023
Q3
$10.7M Sell
959,906
-14,871
-2% -$240K ﹤0.01% 1956
2023
Q2
$20.9M Buy
974,777
+111,461
+13% +$3.29M ﹤0.01% 1558
2023
Q1
$34.9M Sell
863,316
-19,814
-2% -$946K 0.01% 1186
2022
Q4
$41.1M Sell
883,130
-81,277
-8% -$3.71M 0.01% 1047
2022
Q3
$50M Buy
964,407
+33,116
+4% +$1.93M 0.01% 857
2022
Q2
$44M Buy
931,291
+3,198
+0.3% +$174K 0.01% 957
2022
Q1
$66.1M Sell
928,093
-84,071
-8% -$5.47M 0.01% 842
2021
Q4
$75.7M Buy
1,012,164
+53,116
+6% +$4.17M 0.01% 810
2021
Q3
$54.5M Buy
959,048
+310,246
+48% +$15.3M 0.01% 1013
2021
Q2
$28.6M Buy
648,802
+3,888
+0.6% +$190K 0.01% 1632
2021
Q1
$31.8M Buy
644,914
+407,185
+171% +$20.3M 0.01% 1489
2020
Q4
$10M Sell
237,729
-10,312
-4% -$454K ﹤0.01% 2247
2020
Q3
$11.4M Sell
248,041
-6,619
-3% -$321K ﹤0.01% 2042
2020
Q2
$12.8M Sell
254,660
-3,906
-2% -$202K ﹤0.01% 1951
2020
Q1
$13.3M Buy
258,566
+24,268
+10% +$1.29M ﹤0.01% 1697
2019
Q4
$14.5M Sell
234,298
-7,349
-3% -$456K ﹤0.01% 1945
2019
Q3
$14.5M Buy
241,647
+7,610
+3% +$565K ﹤0.01% 1910
2019
Q2
$19.7M Buy
234,037
+2,657
+1% +$239K ﹤0.01% 1704
2019
Q1
$22.1M Sell
231,380
-9,423
-4% -$845K 0.01% 1604
2018
Q4
$17.1M Buy
240,803
+9,207
+4% +$706K ﹤0.01% 1705
2018
Q3
$19.8M Buy
231,596
+7,653
+3% +$767K ﹤0.01% 1808
2018
Q2
$26M Buy
223,943
+32,113
+17% +$3.2M 0.01% 1562
2018
Q1
$15.5M Sell
191,830
-8,527
-4% -$656K ﹤0.01% 1882
2017
Q4
$11.8M Buy
200,357
+4,834
+2% +$242K ﹤0.01% 2081
2017
Q3
$9.15M Sell
195,523
-189
-0.1% -$7.6K ﹤0.01% 2257
2017
Q2
$7.04M Buy
195,712
+7,772
+4% +$249K ﹤0.01% 2403
2017
Q1
$5.79M Sell
187,940
-2,371
-1% -$73.8K ﹤0.01% 2463
2016
Q4
$6.38M Buy
190,311
+7,494
+4% +$215K ﹤0.01% 2386
2016
Q3
$4.86M Buy
182,817
+5,770
+3% +$134K ﹤0.01% 2539
2016
Q2
$3.9M Sell
177,047
-9,326
-5% -$244K ﹤0.01% 2630
2016
Q1
$5.47M Buy
186,373
+5,104
+3% +$142K ﹤0.01% 2354
2015
Q4
$5.99M Buy
181,269
+4,110
+2% +$134K ﹤0.01% 2356
2015
Q3
$6.4M Buy
177,159
+47,120
+36% +$2.02M ﹤0.01% 2296
2015
Q2
$5.85M Buy
130,039
+9,363
+8% +$364K ﹤0.01% 2424
2015
Q1
$3.7M Buy
120,676
+143
+0.1% +$5.56K ﹤0.01% 2701
2014
Q4
$6.13M Sell
120,533
-789
-0.7% -$35.3K ﹤0.01% 2370
2014
Q3
$4.8M Buy
121,322
+64,879
+115% +$2.59M ﹤0.01% 2534
2014
Q2
$2.43M Buy
56,443
+5,204
+10% +$199K ﹤0.01% 2975
2014
Q1
$2.05M Sell
51,239
-2,274
-4% -$82.6K ﹤0.01% 3124
2013
Q4
$1.46M Buy
53,513
+3,977
+8% +$96.4K ﹤0.01% 3276
2013
Q3
$1.14M Buy
49,536
+36,138
+270% +$691K ﹤0.01% 3302
2013
Q2
$237K Buy
+13,398
New +$261K ﹤0.01% 3626

Other funds holding ENTA

Northern Trust's ENTA Position: Q1 2026 in Review

Northern Trust increased its Enanta Pharmaceuticals (ENTA) stake by 4.8% in Q1 2026, buying an estimated $149K and bringing the position to 240,968 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Northern Trust first reported a position in ENTA in Q2 2013 and has held it in 52 quarters since. The position peaked at $75.7M in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Northern Trust held 240,968 shares of Enanta Pharmaceuticals worth $3.04M as of Q1 2026.
  • Northern Trust bought 11,079 Enanta Pharmaceuticals shares in Q1 2026, an estimated $149K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2735 holding.
  • Northern Trust first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Enanta Pharmaceuticals position peaked at $75.7M in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.